Coldstream Capital Management Inc. cut its stake in shares of Eli Lilly And Co (NYSE:LLY) by 2.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,944 shares of the company’s stock after selling 133 shares during the period. Coldstream Capital Management Inc.’s holdings in Eli Lilly And Co were worth $548,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Meridian Wealth Management LLC acquired a new position in Eli Lilly And Co in the first quarter valued at about $38,000. Manchester Financial Inc. acquired a new position in Eli Lilly And Co in the second quarter valued at about $40,000. Litman Gregory Asset Management LLC acquired a new position in Eli Lilly And Co in the second quarter valued at about $47,000. Personal Wealth Partners acquired a new position in Eli Lilly And Co in the second quarter valued at about $53,000. Finally, Kavar Capital Partners LLC acquired a new position in Eli Lilly And Co in the second quarter valued at about $55,000. 76.72% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Alfonso G. Zulueta sold 19,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the sale, the senior vice president now owns 38,306 shares in the company, valued at $4,325,130.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Stephen F. Fry sold 9,452 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the sale, the senior vice president now owns 100,211 shares in the company, valued at approximately $11,524,265. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.
A number of research analysts have issued reports on the company. Bank of America set a $120.00 target price on Eli Lilly And Co and gave the company a “neutral” rating in a research note on Tuesday, September 10th. Goldman Sachs Group assumed coverage on Eli Lilly And Co in a research note on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price for the company. Finally, ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $122.93.
Shares of LLY stock traded up $1.81 on Friday, hitting $116.16. 7,516,310 shares of the stock were exchanged, compared to its average volume of 3,192,564. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98. The firm has a market capitalization of $110.40 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 1.98 and a beta of 0.16. The business has a 50-day moving average of $112.09 and a 200 day moving average of $116.39. Eli Lilly And Co has a fifty-two week low of $104.17 and a fifty-two week high of $132.13.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.05. The company had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. Eli Lilly And Co’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 earnings per share. As a group, research analysts forecast that Eli Lilly And Co will post 5.73 EPS for the current fiscal year.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Trading Strategy Examples and Plans
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.